Johnson & Johnson Reports Solid Q4 Driven by Cancer Drug Sales
Johnson & Johnson (JNJ) exceeded Wall Street estimates for its fourth-quarter revenue and earnings, supported by strong sales of its cancer treatments.
Key Financials:
* Q4 sales: $22.52 billion (5.3% YoY growth)
* Adjusted EPS: $2.04 (10.9% YoY decline)
* 2025 sales guidance: $90.9-$91.7 billion
* 2025 adjusted EPS guidance: $10.75-$10.95
Cancer Drug Sales Drive Growth:
Quarterly sales of J&J's cancer drugs surged 19% worldwide, led by:
* Darzalex: $3 billion in sales, up 20.9% YoY
* Carvykti: $334 million in sales
Acquisitions and Partnerships:
J&J continues to expand through acquisitions, including:
* Intra-Cellular: $14.6 billion deal to enhance psychiatric drug portfolio
* Shockwave Medical: $13.1 billion purchase to strengthen heart device business
Innovative Medicine and Medtech Units Perform Well:
* Innovative medicine unit sales: $14.33 billion
* Medtech unit sales: $8.19 billion
Challenges:
* Stelara sales declined 14.7% due to generic competition
* Annual sales of Darzalex expected to decline in 2025